Drugs / BAY1237592
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03754660 | Jan 2019 → Apr 2022 | pulmonary hypertension | Bayer | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY1237592 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03754660 ↗ |
| Route | Inhaled | “Oral inhalation with dry powder inhaler, single dose.” NCT03754660 ↗ |